Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors

Medicine

Volumn 82, Issue 4, 2003, Pages 282-290

  Zeltser, David ^a   Justo, Dan ^a   Halkin, Amir ^a   Prokhorov, Vitaly ^a   Heller, Karin ^a   Viskin, Sami ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ASTEMIZOLE; CIMETIDINE; CISAPRIDE; DIAZEPAM; DOMPERIDONE; ELECTROLYTE; ERYTHROMYCIN; GATIFLOXACIN; HALOPERIDOL; IMIDAZOLE DERIVATIVE; MACROLIDE; MOXIFLOXACIN; NEUROLEPTIC AGENT; NIFEDIPINE; PROBUCOL; PROPRANOLOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TERFENADINE; TERODILINE; THIORIDAZINE;

ANAMNESIS; ARTICLE; CLINICAL MEDICINE; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG INDUCED DISEASE; ELECTROLYTE DISTURBANCE; FAMILY HISTORY; FEMALE; GENDER; HEART DISEASE; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TORSADE DES POINTES; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; RISK FACTORS; SEX DISTRIBUTION; TORSADES DE POINTES;

EID: 0037823364     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200307000-00007     Document Type: Article

References (172)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SAN. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97: 175-87, 1999.
2. Aldariz AE, Romero H, Baroni M, Baglivo H, Esper RJ. QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin. Pacing Clin Electrophysiol 9: 836-41, 1986.
3. Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsade - is there a link? Int J Cardiol 49: 178-80, 1995.
4. Arizona CERT. QT drug lists. The University of Arizona Center for Education and Research on Therapeutics, Arizona Health Sciences Center, Tucson, AZ. http://www.torsades.org.
5. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 67: 413-8, 2000.
6. Bibler MR, Chou TC, Toltzis RJ, Wade PA. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 94: 1303-6, 1988.
7. Biglin KE, Faraon MS, Constance TD, Lieh-Lai M. Drug-induced torsade de pointes: A possible interaction of terfenadine and erythromycin [letter]. Ann Pharmacother 28: 282, 1994.
8. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high dose cisapride. Arch Intern Med 155: 765-8, 1995.
9. Brandriss MW, Richardson WS, Barold SS. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsade de pointes): Case report and review. Clin Infect Dis 18: 995-8, 1994.
10. Broadhurst P, Nathan AW. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemozole ingestion. Br Heart J 70: 469-70, 1993.
11. Casazza F, Fiorista F, Rustici A, Brambilla G. Torsione di punto da antidpressivi tricilici. G Ital Cardiol 16: 1058-61, 1986.
12. Castot A, Rapoport P, Le Coz P. Prolonged QT interval with halofantrine [letter]. Lancet 341: 1541, 1993.
13. Cavallini B, Spinolo L, Guadagni C, Spitali G. Probucol and malignant ventricular arrhythmias. Presentation of a case. Minerva Cardioangiol 35: 99-100, 1987.
14. Chennareddy SB, Siddique M, Karim MY, Kudesia V. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Am Heart J 132: 691-4, 1996.
15. Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarythromycin. Heart Dis 1: 206-7, 1999.
16. Cointe R, Dussarat GV, Mafart B, Bru P, Levy S. [Arrhythmogenic effects of antidepressive agents demonstrated by programmed ventricular pacing.] Arch Mal Coeur Vaiss 82: 401-4, 1989.
17. Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC. Torsades de pointes ventricular tachycardia and terodiline. Lancet 338: 344-5, 1991.
18. Davies SW, Brecker SJ, Stevenson RN. Terodiline for treating detrusor instability in elderly people. BMJ 302: 1276, 1991.
19. De Koning J, Van der Hoeven H, Hamer B, Thompson J. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with legionella pneumonia. Neth J Med 44: 131-5, 1994.
20. Denvir MA, Sood A, Dow R, Brady AJ, Rankin AC. Thioridazine, diarrhoea and torsades de pointe. J R Soc Med 91: 145-7, 1998.
21. Di Salvo TG, O'Gara PT. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 18: 285-90, 1995.
22. Dorsey ST, Biblo LA. Prolonged QT interval and torsade de pointes caused by the combination of fluconazole and amitryptiline. Am J Emerg Med 18: 227-9, 2000.
23. Douglas PH, Block PC. Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Catheter Cardiovasc Interv 50: 352-5, 2000.
24. Dupont E, Matsushita T, Kaba RA, Vozzi C, Coppen SR, Khan N, Kaprielian R, Yacoub MH, Severs NJ. Altered connexin expression in human congestive heart failure. J Mol Cell Cardiol 331: 359-71, 2001.
25. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointe probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 15: 350-1, 1996.
26. Engrav MB, Coodley G, Magnusson AR. Torsade de pointes after inhaled pentamidine. Ann Emerg Med 21: 1403-5, 1992.
27. Faigel DO, Metz DC, Kochman ML. Torsade de pointes complicating the treatment of bleeding esophageal varices: Association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol 90: 822-4, 1995.
28. Farquhar Zanetti LA, Oliphant CM. Pentamidine-induced torsades de pointes. Ann Pharmacother 28: 282-3, 1994.
29. Fauchier JP, Lanfranchi J, Ginies G, Raynaud R. [Syncope through multifocal ventricular tachycardia during treatment with chloroquine. Study of the hisian electrogram and treatment by verapamil.] Ann Cardiol Angeiol 23: 341-6, 1974.
30. Fayer SA. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J Clin Psychopharmacol 6: 375-6, 1986.
31. Fazekas T, Krassoi I, Lengyel C, Varro A, Papp JG. Suppression of erythromycin-induced early after depolarizations and torsade de pointes ventricular tachycardia by mexiletine. Pacing Clin Electrophysiol 21: 147-50, 1998.
32. Federal Drug Commission. FDA/PhRMA task force to assess QT risk by preclinical markers. Pink Sheet 61: 15-6, 1999.
33. Fletcher GF, Kazamias TM. Cardiotoxic effects of mellaril: Conduction disturbance and supraventricular arrhythmias. Am Heart J 78: 135-8, 1969.
34. Flockhart DA. Cytochrome P450 drug interaction table. Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN. http://medicine.iupui.edu/flockhart/.
35. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 20: 317-24, 2000.
36. Flugelman MY, Tal A, Pollack S, Hefez A, Weisstub EB, Gotsman MS, Lewis BS. Psychotropic drugs and long QT syndromes: Case reports. J Clin Psychiatry 46: 290-1, 1985.
37. Fournier P, Pacouret G, Charbonnier B. [A new cause of torsades de pointes: Combination of terfenadine and troleandomycin.] Ann Cardiol Angeiol 42: 249-52, 1993.
38. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37: 223-30, 1976.
39. Freedman RA, Anderson KP, Green LS, Mason JW. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 59: 168-9, 1987.
40. Gabel A, Schymik G, Mehmel HC. Ventricular fibrillation due to long QT syndrome probably caused by clindamycin. Am J Cardiol 83: 813-5, 1999.
41. Giles TD, Modlin RK. Death associated with ventricular arrhythmia and thiorazide hydrochloride. JAMA 205: 108-10, 1968.
42. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 105: 368-72, 1994.
43. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsades de pointes) associated with the use of probucol. N Engl J Med 326: 1435-6, 1992.
44. Gonzalez A, Sager PT, Akil B, Rahimtoola SH, Bhandari AK. Pentamidine-induced torsade de pointes. Am Heart J 122: 1489-92, 1991.
45. Goss JE, Ramo BW, Blake K. Torsades de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 153: 2705, 1993.
46. Gray VS. Syncopal episodes associated with ciaspride and concurrent drugs. Ann Pharmacother 32: 648-51, 1998.
47. Green PT, Reents S, Harman E, Curtis AB. Pentamidine-induced torsades de point in a renal transplant recipient with pneumocystis carinii pneumonia. South Med J 83: 481-4, 1990.
48. Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent torsade de pointes during erythromycin lactobionate infusion. Am J Cardiol 58: 666, 1986.
49. Gueugniaud PY, Guerin C, Mahul P, Deu C, Robert D. Torsades de pointes induites par l'associacion lidocaine erythromycine et insuffisance hepatiq. Presse Med 14: 896, 1985.
50. Guzzini F, Baroffio R, Coppetti D, Gasparini P. Aritmie ventriculare gravi secondarie a ipopotassiemia indotta dall'indapamide. Clin Ter 135: 283-7, 1990.
51. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 22: 672-4, 1999.
52. Heiman EM. Cardiac toxicity with thioridazine-tricyclic antidepressant combination. J Nerv Ment Dis 165: 139-43, 1977.
53. Herrmann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 51: 904-6, 1983.
54. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI. Proarrhythmia associated with cisapride in children. Pediatrics 101: 1053-6, 1998.
55. Hoehns JD, Stanford RH, Garaets DR, Skelly KS, Lee HC, Gaul BL. Torsades de pointes associated with chlorpromazine: Case report and review of associated ventricular arrhythmias. Pharmacotherapy 21: 871-83, 2001.
56. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269: 1513-8, 1993.
57. Hsieh MH, Chen SA, Chiang CE, Tai CT, Lee SH, Wen ZC, Chang MS. Drug-induced torsade de pointes in one patient with congenital long QT syndrome. Int J Cardiol 54: 85-8, 1996.
58. Hunt N, Stern TA. The association between intravenous haloperidol and torsades de pointes. Three cases and a literature review. Psychosomatics 36: 541-9, 1996.
59. Iannini PB, Doddamani S, Byazrova B, Circiumaru I, Kramer H. Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ 322: 1158-9, 2001.
60. Iglesias E, Esteban E, Zabala S, Gascon A. Tiapride induced torsade de pointes. Am J Med 109: 509, 2000.
61. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157: 2013-5, 1997.
62. Johnson MC, So S, Marsh JW, Murphy AM. QT prolongation and torsades de pointes after administration of FK506. Transplantation 53: 929-30, 1992.
63. Kajinami K, Takekoshi N, Mabuchi H. Propranolol for probocol induced QT prolongation with polymorphic ventricular tachycardia. Lancet 341: 124-5, 1993.
64. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 34: 92-5, 1995.
65. Kamochi H, Nil T, Eguchi K, Mori T, Yamamoto A, Shimoda K, Ibarakai K. Clarithromycin associated with torsades de pointes. Jpn Circ J 63: 421-2, 1999.
66. Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D. A review of erythromycin-induced malignant tachyarrhythmia torsade de pointes. A case report. Angiology 48: 821-6, 1997.
67. Kawasaki R, Machado C, Reinoehl J, Fromm B, Baga JJ, Steinman RT, Lehman MH. Increased propensity of women to develop torsade de pointes during complete heart block. J Cardiovasc Electrophysiol 6: 1032-8, 1995.
68. Kelly HG. Thioridazide hydrochloride (mellaril): Its effects on the electrocardiogram and a report of two fatalities with electrocardigoraphic abnormalities. Can Med Assoc J 89: 546-54, 1963.
69. Kelly KJ, Stang JM, Mekhjian HS. Vasopressin provocation of ventricular dysrrhythmia. Ann Intern Med 92: 205-6, 1980.
70. Kemper AJ, Dunlap R, Pietro DA. Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol. JAMA 249: 2931-4, 1983.
71. Khan MM, Logan KR, McComb JM, Adgey AA. Management of recurrent ventricular tachyarrhythmias associated with Q-T prolongation. Am J Cardiol 47: 1301-8, 1981.
72. Kiriike N, Maeda Y, Nishiwaki S, Izumiya Y, Katahara S, Mui K, Kawakita Y, Nishikimi T, Takeuchi K, Takeda T. Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 22: 99-103, 1987.
73. Kocheril AG, Bokhari SAJ, Batsford WP, Sinusas AJ. Long QTc and torsade de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 20: 2810-6, 1997.
74. Kondou N, Hiasa Y, Kishi K, Fujinaga H, Ohishi Y, Ohtani R, Wada T, Aihara T. [A case of life-threatening ventricular arrhythmias probably due to psychotropic drugs.] Kokyu To Junkan 41: 1117-20, 1993.
75. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y. Haloperidol-induced torsades de pointes. Chest 98: 482-4, 1990.
76. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 104: 395-6, 1998.
77. Lee WR, Sheikh MU, Covarrubias EA, Slotkoff LM. Variant ventricular tachycardia in desipramine toxicity. South Med J 74: 1268-9, 1981.
78. Leitersdorf E, Goshen R, Shefer A. Atypical ventricular tachycardia in combined tetracyclic, antidepressant, neuroleptic and anticholinergic drugs interaction. Int J Psychiatry Med 12: 85-91, 1982.
79. Lewis BH, Antman EM, Graboys TB. Detailed analysis of 24 hour ambulatory electrocardiographic recordings during ventricular fibrillation or torsade de pointes. J Am Coll Cardiol 2: 426-36, 1983.
80. Liberatore MA, Robinson DS. Torsade de pointes: A mechanism of sudden death associated with neuroleptic drug therapy? J Clin Psychopharmacol 4: 143-6, 1984.
81. Lin JC, Quasny HA. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 17: 626-30, 1997.
82. Lindsay J, Smith JA, Light JA. Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 98: 222-3, 1990.
83. Loescher T, Loeschke K, Niebel J. Severe ventricular arrhythmia during pentamidine treatment of AIDS associated Pneumocystis carinii pneumonia [letter]. Infection 15: 455, 1987.
84. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 59: 376-7, 1987.
85. MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine [letter]. BMJ 302: 1469, 1991.
86. Magorien RD, Jewell GM, Schaal SF, Leier CV. Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation. Am J Med 67: 353-7, 1979.
87. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehman MH. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. J Am Med Assoc 270: 2590-7, 1993.
88. Mallory DL, Parrillo JE, Bailey KR, Akin GL, Brenner M, Lane HC, Fauci AS, Masur H. Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. Crit Care Med 15: 503-5, 1987.
89. Massari FM, Trevano FQ, Diehl L, Romano S. Long QT interval and malignant ventricular arrhythmia during treatment with cisparide. Report of a clinical case. Ital Heart J 1: 1055-8, 2000.
90. Matsis PP, Easthope RN. Torsades de pointes ventricular tachycardia associated with terfenadine and paracetamol self medication. N Z Med J 107: 402-3, 1994.
91. Matsuhashi H, Onodera S, Kawamura Y, Hasebe N, Kohmura C, Yamashita H, Tobise K. Probucol-induced QT prolongation and torsades de pointes. Jpn J Med 28: 612-5, 1989.
92. Mauro VF, Bingle JF, Ginn SM, Jafri FM. Torsade de pointes in a patient receiving intravenous vasopressin. Crit Care Med 16: 200-1, 1988.
93. Mazur A, Strasberg B, Kusniec J, Sclarovsky S. QT prolongation and polymorphous ventricular tachycardia associated with trasodone-amiodarone combination. Int J Cardiol 52: 27-9, 1995.
94. McComb JM, Campbell NP, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 54: 922-3, 1984.
95. McLeod AA, Thorogood S, Barnett S. Torsades de pointes complicating treatment with terodiline. BMJ 302: 1469, 1991.
96. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 13: 128-32, 1993.
97. Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32: 761-5, 1998.
98. Mitchell P, Dodek P, Lawson L, Kiess M, Russell J. Torsades de pointes during intravenous pentamidine isethionate therapy. CMAJ 140: 173-4, 1989.
99. Molloy DW, Penner SB, Rabson J, Hall KW. Use of sodium bicarbonate to treat tricyclic antidepressant-induced arrhythmias in a patient with alkalosis. Can Med Assoc J 130: 1457-9, 1984.
100. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantinela LR. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 264: 2788-90, 1990.
101. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Biamchi L, Pinnavaia A, Aquaro G, Priori SG. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life threatening arrhythmias. J Cardiovasc Electrophysiol 11: 691-6, 2000.
102. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 89: 235-8, 1990.
103. Ng KS, Tham LS, Tan HH, Chia BL. Cisapride and torsades de pointes in a pacemaker patient. Pacing Clin Electrophysiol 23: 130-2, 2000.
104. Ng PW, Chan WK, Chan TY. Torsades de pointes during the concomitant use of terfenadine and cimetidine. Aust N Z J Med 26: 120-1, 1996.
105. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NG. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-6, 1993.
106. Oberg K, Bauman J. QT interval prolongation and torsade de pointes due to erythromycin lactobionate. Pharmacotherapy 15: 687-92, 1996.
107. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 33: 1046-50, 1999.
108. Ochiai H, Kashiwagi M, Usui T, Oyama Y, Tokita Y, Ishikawa T. [Torsade de pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: Report of a case.] Kokyu To Junkan 38: 819-22, 1990.
109. Orban Z, MacDonald LL, Peters MA, Guslits B. Erythromycin-induced cardiac toxicity. Am J Cardiol 75: 859-61, 1995.
110. Osbome RJ, Slevin ML, Hunter RW, Hamer J. Cardiac arrhythmias during cytotoxic chemotherapy: Role of domperidone. Hum Toxicol 4: 617-26, 1985.
111. Otsuka M, Kanamori H, Sasaki S, Taguchi J, Harano H, Ogawa K, Matsuzaki M, Mohri H, Okubo T, Sumita S, Ochia J. Torsades de pointes complicating pentamidine therapy of pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med 36: 705-8, 1997.
112. Paltoo B, O'Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 24: 895-7, 2001.
113. Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP. Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 12: 636-8, 1994.
114. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth 47: 251-4, 2000.
115. Pettignano R, Chambliss CR, Darsey E, Heard M, Clark R. Cisapride-induced dysrhythmia in a pediatric patient receiving extra-corporeal life support. Crit Care Med 24: 1268-71, 1996.
116. Pietro DA. Thioridazine-associated ventricular tachycardia and isoproterenol. Ann Intern Med 94: 411, 1981.
117. Pinto YM, Van-Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life threatening arrhythmias associated with fexofenadine. Lancet 353: 980, 1999.
118. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 33: 22-6, 1999.
119. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 45: 191-3, 1993.
120. Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. BMJ 306: 186, 1993.
121. Quek DK, H'ng PK. Torsade de pointes and sudden death associated with diabetic autonomic diarrhoea - a case report. Singapore Med J 34: 266-70, 1993.
122. Raehl CL, Patel AK, LeRoy M. Drug-induced torsade de pointes. Clin Pharm 4: 675-90, 1985.
123. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 86: 465-6, 1989.
124. Rao KA, Adlakha A, Verma-Ansil B, Meloy TD, Stanton MS. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clin Proc 69: 589-93, 1994.
125. Ravin DS, Levenson JW. Fatal cardiac event following initiation of Risperdone therapy. Ann Pharmacother 31: 867-70, 1997.
126. Reinoehl J, Frankovich D, Machado C, Raymond K, Baga JJ, Pires LA, Steinman RA, Fromm BS, Lehmann MH. Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender. Am Heart J 131: 1184-91, 1996.
127. Rezkalla M, Pochop C. Erythromycin induced torsade de pointes: Case report and review of the literature. S D J Med 47: 161-4, 1994.
128. Rialan A, Richard M, Deutsch P, Ouattara B. Torsades de pointes chez une patiente traitee au long cours par maprotiline. Ann Cardiol Angeiol 45: 123-5, 1996.
129. Roden DM. Taking the "idio" out of "idiosyncratic:" Predicting torsades de pointes. Pacing Clin Electrophysiol 21: 1029-34, 1998.
130. Rosenquist RJ, Brauer WW, Mork JN. Recurrent major ventricular arrhythmias associated with thioridazine therapy. Minn Med 54: 877-80, 1971.
131. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 289: 1579, 1984.
132. Sakemi H, VanNatta B. Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J 125: 1436-8, 1993.
133. Salerno DM, Murakami MM, Winston MD, Elsperger KJ. Postresuscitation electrolyte changes: Role of arrhythmia and resuscitation efforts in their genesis. Crit Care Med 17: 1181-6, 1989.
134. Samaha F. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 107: 528-9, 1999.
135. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsades de pointes). BMJ 300: 1375-6, 1990.
136. Schoonmaker FW, Osteen RT, Greenfield JCJ. Thioridazide (melleril) induced ventricular tachycardia controlled with an artificial pacemaker. Ann Intern Med 65: 1076-8, 1966.
137. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisaprid and clarythromycin. Am J Kidney Dis 30: 437-9, 1997.
138. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30: 17-26, 1964.
139. Sesti F, Abbott GW, Wei J, Murray K, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL, Goldstein SA. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 97: 10613-8, 2000.
140. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 81: 238-40, 1998.
141. Shivkumar K. Images in cardiovascular medicine. Labile repolarization from "cell to bedside". Circulation 102: 817-8, 2000.
142. Short TG, Maling T, Galletly DC. Ventricular arrhythmia precipitated by flumazenil. Br Med J (Clin Res Ed) 296: 1070-1, 1988.
143. Simons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsades de pointes. Lancet 2: 624, 1988.
144. Sipido KR, Volders PG, De-Groot SH, Verdonck F, Van-de-Werf F, Wellens HJ, Vos MA. Enhanced Ca(2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: Potential link between contractile adaptation and arrhythmogenesis. Circulation 24: 2137-44, 2000.
145. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA. Contraindicated use of cisapride: Impact of food and drug administration regulatory action. JAMA 284: 3036-9, 2000.
146. Stein KM, Haronian H, Mensah GA, Acosta A, Jacobs J, Kligfield P. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 66: 888-9, 1990.
147. Stein LB, Dabezies MA, Silverman M, Brozena SC. Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin [letter]. J Clin Gastroenterol 15: 171-4, 1992.
148. Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42: 577-80, 1992.
149. Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K. Doxepin induced torsade de pointes. Pacing Clin Electrophysiol 5: 873-7, 1982.
150. Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: A review of the literature and possible mechanisms. J Forensic Sci 42: 335-9, 1997.
151. Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 18: 381-5, 1998.
152. Toivonen L, Viitasalo M, Siikamaki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 17: 403-4, 1994.
153. Tri TB, Combs DT. Phenothiazine induced ventricular tachycardia. West J Med 123: 412-6, 1975.
154. Troendle G, Guerigian J, Sobel S, Johnson M. Probucol and the QT interval. Lancet 1: 1179, 1982.
155. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 96: 144-6, 1997.
156. Tsuji Y, Opthof T, Kamiya K, Yasui K, Liu W, Lu Z, Kodama I. Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res 48: 300-9, 2000.
157. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97: 1514-6, 2001.
158. Van Der Klauw MM, Van Rey FJ, Stricker BH. Polymorfe ventriculaire tachycardie met torsades de pointes bij gebruik van terodiline (mictrol). Ned Tijdschr Geneeskd 136: 91-3, 1992.
159. Varma S, Achan K. Dysrhythmia associated with clozapine. Aust N Z J Psychiatry 33: 118-9, 1999.
160. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med 327: 846-52, 1992.
161. Viskin S. The long QT syndromes and torsade de pointes. Lancet 354: 1625-33, 1999.
162. Viskin S, Fish R, Roden DM. Drug induced torsade de pointes. In: Braunwald E, Fauci SA, Isselbacher KJ, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 14th ed, pp 231, 2000. http://harrisonsonline.com.
163. Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsade de pointes. J Cardiovasc Electrophysiol 9: 1109-113, 1999.
164. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28: 1556-61, 1996.
165. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med 131: 797, 1999.
166. Wharton JM, Demopulos P, Goldschlager N. Torsade de pointes during administration of pentamidine isethianate. Am J Med 83: 571-6, 1987.
167. Wiener I, Rubin DA, Martinez E, Postman J, Herman MV. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole. Mt Sinai J Med 48: 53-5, 1981.
168. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 119: 391-4, 1993.
169. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of cardiotoxic actions of terfenadine. JAMA 269: 1532-6, 1993.
170. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: Implications for torsades de pointes and reverse use-dependence. Circulation 93: 407-11, 1996.
171. Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler KU, Just H. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multi-center Ketanserin Research Group. Clin Physiol Biochem 8: 90-100, 1990.
172. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A. Torsade de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 13: 1002-3, 1992.